Use of rapamycin and rapamycin derivatives for the treatment of bone loss

Details for Australian Patent Application No. 2004255340 (hide)

Owner Novartis AG

Inventors Kneissel, Michaela; Susa Spring, Mira

Agent Davies Collison Cave

Pub. Number AU-B-2004255340

PCT Pub. Number WO2005/005434

Priority 0315963.9 08.07.03 GB; 0315965.4 08.07.03 GB

Filing date 7 July 2004

Wipo publication date 20 January 2005

Acceptance publication date 1 May 2008

International Classifications

A61K 31/436 (2006.01)

A61P 19/00 (2006.01) Drugs for skeletal disorders

C07D 498/18 (2006.01) Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms

Event Publications

19 January 2006 PCT application entered the National Phase

  PCT publication WO2005/005434 Priority application(s): WO2005/005434

1 May 2008 Application Accepted

  Published as AU-B-2004255340

28 August 2008 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004255342-Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds

2004255338-Thiophenylaminoimidazolines as prostaglandin I2 antagonists